Research and Markets: Pulmonary Arterial Hypertension Pipeline Insights 2015 - Provides a Pulmonary Arterial Hypertension Landscape across the Globe

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/dvb9jt/pulmonary) has announced the addition of the "Pulmonary Arterial Hypertension-Pipeline Insights" report to their offering.

Pulmonary Arterial Hypertension- Pipeline Insights provides the in-depth analysis of the pipeline assets across the Pulmonary Arterial Hypertension. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The Pulmonary Arterial Hypertension Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

Pulmonary Arterial Hypertension- Pipeline Insights Report covers the Pulmonary Arterial Hypertension pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides Pulmonary Arterial Hypertension related therapeutic assessments by molecule type, route of administration, monotherapy and combination products.

Scope

  • The report provides a Pulmonary Arterial Hypertension Landscape across the globe
  • The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information
  • Coverage of the Pulmonary Arterial Hypertension pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Pulmonary Arterial Hypertension and also provide company profiling

Key Topics Covered:

  • Pulmonary Arterial Hypertension Overview
  • Pulmonary Arterial Hypertension Pipeline Therapeutics
  • Pulmonary Arterial Hypertension Therapeutics under Development by Companies
  • Pulmonary Arterial Hypertension Late Stage Products (Filed and Phase III)
  • Comparative Analysis
  • Pulmonary Arterial Hypertension Mid Clinical Stage Products (Phase II)
  • Comparative Analysis
  • Pulmonary Arterial Hypertension Early Clinical Stage Products (Phase I and IND Filed)
  • Comparative Analysis
  • Pulmonary Arterial Hypertension Discovery and Pre-Clinical Stage Products
  • Comparative Analysis
  • Drug Candidate Profiles
  • Pulmonary Arterial Hypertension - Therapeutics Assessment
  • Assessment by Monotherapy Products
  • Assessment by Combination Products
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Pulmonary Arterial Hypertension - Discontinued Products
  • Pulmonary Arterial Hypertension - Dormant Products
  • Companies Involved in Therapeutics Development for Pulmonary Arterial Hypertension

For more information visit http://www.researchandmarkets.com/research/dvb9jt/pulmonary

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals